Inferring antibiotic mechanisms on translation through static structures has been challenging, as biological systems are highly dynamic. Dynamic single-molecule methods are also limited to few simultaneously measurable parameters. We have circumvented these limitations with a multifaceted approach to investigate three structurally distinct aminoglycosides that bind to the aminoacyl-transfer RNA site (A site) in the prokaryotic 30S ribosomal subunit: apramycin, paromomycin, and gentamicin. Using several single-molecule fluorescence measurements combined with structural and biochemical techniques, we observed distinct changes to translational dynamics for each aminoglycoside. While all three drugs effectively inhibit translation elongation, their actions are structurally and mechanistically distinct. Apramycin does not displace A1492 and A1493 at the decoding center, as demonstrated by a solution nuclear magnetic resonance structure, causing only limited miscoding; instead, it primarily blocks translocation. Paromomycin and gentamicin, which displace A1492 and A1493, cause significant miscoding, block intersubunit rotation, and inhibit translocation. Our results show the power of combined dynamics, structural, and biochemical approaches to elucidate the complex mechanisms underlying translation and its inhibition.
INTRODUCTION
The ribosome is the molecular machine that rapidly and accurately interprets the genetic code on the messenger RNA (mRNA) to synthesize proteins (Green and Noller, 1997) . During elongation, the ribosome repeats the cycle of selecting a transfer RNA (tRNA) molecule matching the codon in the 30S A site, incorporating the amino acid from the selected A-site tRNA into the polypeptide on the P-site tRNA, translocating the A-and P-site tRNAs to the P and E sites, and stepping precisely three bases in the 3 0 direction (Korostelev et al., 2008; Wintermeyer et al., 2004; Zaher and Green, 2009 ). To elongate with an optimal balance of speed and accuracy, the ribosome employs G protein elongation factors (elongation factor thermo unstable [EF-Tu] and elongation factor G [EF-G] in bacteria) to facilitate key steps during the process (Nilsson and Nissen, 2005) . Using the energy from guanosine triphosphate (GTP) hydrolysis, EF-Tu enhances the rate and specificity of tRNA selection and EF-G catalyzes translocation.
The central role of translation makes the ribosome a rich target for clinically important small-molecule antibiotics. They employ diverse strategies to interfere with translation and fall into several distinct classes, including macrolides, tetracyclines, and aminoglycosides (Benveniste and Davies, 1973; Bö ttger, 2006; Davies et al., 1965; Perzynski et al., 1979; Woodcock et al., 1991) . Biochemical and structural studies of these antibiotics have shed light on their mechanism and have, in turn, provided clues to the molecular workings of the ribosome and its ligands (Yonath, 2005) . Here, we focus on the clinically important aminoglycosides as a representative group of translational inhibitors.
Aminoglycosides contain a central deoxystreptamine ring with amino-sugar modifications (4,5 and 4,6 disubstituted deoxystreptamine) and include neomycin, paromomycin, gentamicin, kanamycin, and the fused-ring compound, apramycin. Aminoglycosides disrupt the fidelity of tRNA selection and block translocation (Benveniste and Davies, 1973; Davies and Davis, 1968; Davies et al., 1965) . Nuclear magnetic resonance (NMR) and X-ray crystal structures as well as biochemical and molecular biological studies (Bö ttger et al., 2001; Powers and Noller, 1991) have revealed the structural basis for specific aminoglycoside binding to bacterial ribosomes. Aminoglycosides bind in the major groove of the 16S ribosomal RNA (rRNA) decoding site, forming specific contacts with conserved nucleotides G1494 and U1495; ring I of the aminoglycosides fits into a prokaryote-specific binding pocket formed by universally conserved nucleotides A1492 and A1493 and the prokaryotic-specific nucleotide A1408, imparting their specificity (Bö ttger et al., 2001; Recht et al., 1999) .
These structural studies suggested a mechanism for aminoglycoside action ( Figure 1A ). In the presence of a cognate codon-anticodon complex, A1492 and A1493 (Moazed and Noller, 1990 ) make shape-specific contacts in the minor groove of the codon-anticodon A-form helix Ogle et al., 2001; Yoshizawa et al., 1999) . These contacts assist in distinguishing between correct and incorrect codon-anticodon pairings, as shown by both structural and kinetic investigations. In the absence of tRNA or drug, A1492/A1493 are stacked within an asymmetric internal loop at the base of Helix 44 (h44). Upon codon-anticodon interaction, A1492/A1493 are displaced from h44 to make the contacts discussed above. Binding of either 4,5 or 4,6 disubstituted aminoglycosides to the decoding site mimics this conformational effect, displacing A1492 and A1493 toward the minor groove.
Aminoglycosides alter the kinetics of tRNA accommodation, supporting these structural predictions (Pape et al., 1998 (Pape et al., , 2000 . Paromomycin significantly reduces the dissociation rate of near-cognate tRNA and increases the rate of GTPase activation on EF-Tu by an order of magnitude. These results suggest that aminoglycosides stabilize near-cognate tRNA binding to the ribosome with a 16S rRNA conformation that mimics cognate codon-anticodon recognition. While the structural basis of aminoglycoside-induced miscoding has become clear, little is known about how they inhibit the subsequent steps of elongation. The relative importance of miscoding and inhibiting translocation to the potency of the drugs has not been determined. The location where aminoglycosides bind to the bacterial ribosome is shown. The detailed binding site is shown to the right, with the A-site tRNA in orange and paromomycin in red. The three nucleotides in blue are A1408, which is specific to prokaryotes and conveys the specificity of aminoglycosides, and A1492/A1493, which are destacked by aminoglycosides and mimic the conformation of correct codon-anticodon recognition between the mRNA and the A-site tRNA. A-site structure with paromomycin is rendered from PDB 2J00 (Selmer et al., 2006) . (B-D) The structures of the three aminoglycosides tested. Biochemical experiments have shown that aminoglycosides induce miscoding and block translocation. Such effects were also seen in our single-molecule assays, as shown in Figure S1 .
Here, we use a combined dynamics and structural approach to understand how distinct aminoglycosides disrupt translation.
We probed the mechanism of translational inhibition by an aminoglycoside from each of the three distinct structural classes: apramycin (fused-ring), paromomycin (4,5-linked) , and gentamicin (4,6-linked) ( Figures 1B-1D ) using single-molecule, structural, and biochemical approaches. We solved the solution structure of apramycin bound to the bacterial decoding site by NMR spectroscopy, providing a structure to the repertoire of drug-RNA complexes. We determined the effects of all three drugs on the dynamics of translation using an array of single-molecule techniques : we monitored the global conformation of the ribosome during elongation and the dynamics of tRNA accommodation by fluorescence resonance energy transfer (FRET) (Blanchard et al., 2004a) and used zero-mode waveguides (ZMW) to track multiple tRNAs through several elongation cycles at near physiological concentrations (Levene et al., 2003; Uemura et al., 2010) . We also used bulk kinetics (Johansson et al., 2011) to measure the effects of aminoglycosides on rates of peptide bond formation and subsequent translocation. This combination of single-molecule dynamics, structural, and biochemical techniques reveals the mechanism of aminoglycoside action at an unparalleled level of detail.
RESULTS

Apramycin, Paromomycin, and Gentamicin Target Distinct Aspects of the Elongation Cycle
To monitor the global effects of aminoglycosides on elongation, we used intersubunit FRET between site-specifically labeled Escherichia coli 30S and 50S subunits Dorywalska et al., 2005; Marshall et al., 2008 ) that enable real-time monitoring of single ribosomes performing multiple elongation cycles. For each cycle of elongation, the ribosome rotates the 30S body relative to the 50S and then reverses the rotation, controlled respectively by peptide bond formation upon tRNA accommodation and translocation. The nonrotated state is detected by high FRET and the rotated state by a lower FRET value. The resultant FRET cycles report on the processivity and dynamics of the ribosome at each codon (Figures 2A and 2B) . All three aminoglycosides significantly inhibited elongation efficiency (Figures S1A-S1C; see Extended Results for details). To probe the mechanistic origins 
. Aminoglycosides Inhibit Translation Elongation at Different Stages
(A) The intersubunit FRET signal involves cycles between a high FRET state where the 30S body of the ribosome is not rotated relative to the 50S subunit and a low FRET state, where the 30S body is rotated. From previous studies Marshall et al., 2008) , peptide bond formation rotates the 30S body and causes a transition from high to low FRET. EF-G translocates and counterrotates the 30S body, causing a low to high FRET transition. (B) An example trace of the intersubunit FRET, where the ribosome translated the entire 6(FK) mRNA. The zoomed panel directly below the diagram in (A) illustrates the changes in FRET state over one elongation cycle. (C-F) The lifetimes that each ribosome spends in a conformation state over a given codon are fitted to a single exponential decay function and plotted. From left to right, the conditions are no aminoglycosides (C, n = 381), 1 mM apramycin (D, n = 429), 1 mM paromomycin (E, n = 264), and 1 mM gentamicin (F, n = 297). Error bars are SD errors. Different aminoglycosides target different aspects of translation elongation. See also Figure S2 for lifetimes from additional experiments. of translation inhibition by each aminoglycoside, we leveraged the ability of this single-molecule FRET approach to detect codon-specific effects on the dynamics of 30S body rotation and counterrotation during elongation ( Figures 2C-2F and S2A-S2D) Marshall et al., 2008) .
At 1 mM, apramycin did not measurably affect the lifetime ($4 s) of the high-FRET, or nonrotated state, where the ribosome selects tRNA and performs peptidyl transfer. In contrast, apramycin lengthened the low FRET, or rotated state, where the ribosome waits for EF-G to drive translocation by 2-fold from 5 s without drugs to $10 s. Increasing apramycin concentration to 10 mM further increased the rotated ribosome lifetime to 3-fold ($15 s) longer than minus drugs, but did not otherwise introduce any additional effects on elongation. Increasing the EF-G concentration to 160 nM (from 80 nM, Figures S2E-S2G ) partially rescued the rotated ribosome lifetime (1.6-fold longer than that minus drugs [$8 s] ).
At 1 mM paromomycin, the nonrotated state lifetime of the ribosome at the first codon was increased 2-fold ($10 s), but was unaffected at subsequent codons. Paromomycin also lengthened the rotated state lifetime to a lesser extent by 1.4-fold ($7 s). Increasing the concentration to 10 mM further lengthened the first nonrotated state lifetime to 3-fold ($15 s) and the rotated state lifetimes to 2-fold of minus drugs ($10 s). Additionally, paromomycin lengthened the rotated state specifically over the first codon to 4-fold ($20 s) from normal. However, this effect is not observed at 1 mM, suggesting a possible alternative binding site (Borovinskaya et al., 2007) . Overall, paromomycin displays a more complex set of effects on the elongation cycle and appears to participate in unique interactions with the ribosome at the first codon of the mRNA.
At 1 mM, gentamicin had the most severe effects on the nonrotated state lifetime, lengthening it by 3-fold ($15 s) across all codons, suggesting a mechanism distinct from paromomycin. However, similar to paromomycin, gentamicin slightly lengthened the rotated lifetime of the ribosome by 1.6-fold ($8 s). Addition of 10 mM gentamicin led to no further increase in the nonrotated ribosome lifetime; however, similar to paromomycin, a secondary effect of a lengthened rotated ribosome lifetime (to $14 s, a 2.8-fold increase over no drugs) over the first codon was observed.
In addition to impacting different phases of elongation, the three aminoglycosides also induce different levels of miscoding, as described in the Extended Results ( Figures S1D-S1F ).
Following Real-Time tRNA Transit and Sampling in the Presence of Aminoglycosides Using ZMW We next probed the dynamics of aminoglycoside action from the perspective of tRNA binding by directly tracking in real-time labeled tRNA binding and transit through the ribosome in zero mode waveguides (ZMW). The sequence, frequency, and length of each tRNA signal report on the fidelity of tRNA selection and on the speed of elongation was based on the dwell time of the tRNA ( Figures 3A and 3B) . We have used this approach previously to track ribosomal compositional dynamics during initiation and elongation (Tsai et al., 2012; Uemura et al., 2010) .
In the absence of aminoglycosides, stable binding and transit of multiple tRNAs on the ribosome were observed as regular pulse cycles of repeating Cy5 followed by Cy2 signals with regular times between pulses of 10$20 s ( Figures 3C, 3D , and S3A-S3C), as observed previously (Uemura et al., 2010) . In the presence of 10 mM apramycin, the time between pulses lengthened significantly to 30$40 s, a nearly 2-fold increase, where the pulse sequence was still recognizable. Addition of 10 mM paromomycin and gentamicin introduces frequent metastable tRNA binding events of the length of 1 $ 5 s, and the sequences of those events do not match the codon sequence of the 6(FK) mRNA used for the experiments ( Figure 3E ). The abundance of these short-lived events complicates the identification of binding events, resulting in accommodation and translocation. See the Extended Results for the detailed analysis on how the aminoglycosides alter tRNA binding behavior ( Figures S3D-S3F ). This result is consistent with our intersubunit FRET experiments that both aminoglycosides severely impact tRNA selection.
Following Real-Time tRNA Dynamics in the Presence of Aminoglycosides
To delineate the distinct effects of aminoglycosides on tRNA sampling and selection, we followed FRET between a P-site fMet-(Cy3)tRNA fMet and an incoming A-site Phe-(Cy5)tRNA Phe in the presence of antibiotics for an mRNA coding for MetPhe-Lys (MFK). The evolution of this FRET signal reports on the decoding and accommodation of the A-site tRNA as well as classical to hybrid state fluctuations of the tRNA after peptide bond formation (Blanchard et al., 2004b; Figures 4 and S4A-S4C) . Apramycin did not significantly alter the dynamics of tRNA compared to no drugs. In both cases, FRET events proceeded to a high (0.8) FRET state within 100 ms of the appearance of FRET and subsequently fluctuated between high (0.8) and medium (0.5) FRET, consistent with rapid tRNA selection and accommodation and peptide bond formation followed by classical-hybrid dynamics (Blanchard et al., 2004b) . However, apramycin increased the overall tRNA FRET lifetime from 10 s in the absence of drugs to 18 s (Table S1 ). By blocking of translocation, apramycin could prevent the eventual dissociation of tRNA fMet from the E site, preserving FRET.
In contrast, paromomycin significantly altered the behavior of tRNA on the ribosome and induces many short-lived excursions (<1 s) from zero FRET to a high (>0.7) FRET level consistent with accommodated tRNA ( Figure S4F ). These events dropped the total FRET lifetime to 1.7 s. While these events are too long to be tRNA sampling attempts (<30 ms), they are much shorter than normal tRNA accommodation without drugs. Longer-lived (1$5 s) high-FRET events with little to no classical-hybrid state fluctuations were also observed ( Figure S4G ), consistent with single-molecule FRET measurements by Blanchard and coworkers (Feldman et al., 2010) . Together with our ZMW measurements, these data suggest that paromomycin stabilizes tRNAs when they sample the A site and shifts the classicalhybrid tRNA conformation equilibrium strongly toward the classical state. The addition of EF-G enriched longer-lived events, as described in the Extended Results ( Figure S4C ).
Gentamicin induced behavior similar to that of paromomycin in tRNA-tRNA FRET experiments, with short (<1 s) high-FRET events suggesting that the A-site tRNA has proceeded nearly to accommodation. A longer-lived high-FRET population with limited exchanges between the classical and hybrid tRNA conformations was also observed. These high-FRET events are longer lived than those observed in paromomycin, with a lifetime approaching the photobleaching time of the FRET pair (18 s). The overall fraction of the short-lived population is also , tRNA binding behavior and sequence can be observed and tRNA transit through the ribosome can be tracked. The tRNA signal lifetimes, wait times between tRNA events, and the frequency of the events can be tracked. (B) An example trace of a tRNA transit experiment without aminoglycosides. The pulse sequence up to the last codon on the 6(FK) mRNA is well-behaved and can be analyzed codon-by-codon. Over the stop codon, short tRNA events are observed as tRNA sampling in the ribosomal A site. These types of events are greatly increased in the presence of paromomycin and gentamicin. (C and D) The waiting times until the next tRNA event over each codon are plotted for the Phe (C) and Lys (D) codons. All error bars are SD. Paromomycin and gentamicin induce too many short tRNA events with the wrong sequence, which precludes an accurate analysis, as exemplified by the bottom two traces with 10 mM gentamicin. (E) Many short tRNA binding events, whose sequence does not conform to the repeating Phe-Lys sequence encoded in the 6(FK) mRNA used in this experiment. (F) A ribosome stalls after the first one or two codons and does not restart until nearing the end of the 300 s observation time in ZMW experiments. See also Figure S3 for additional analysis of ZMW experiments. lower than paromomycin, as shown in the higher relative density of the long events in the postsynchronized plot and the longer total tRNA lifetime (6.8 s). These differences suggest a mechanism distinct from paromomycin.
Paromomycin Induces Miscoding
To probe how paromomycin alters tRNA selection fidelity, we repeated our tRNA-tRNA FRET experiments with an mRNA encoding Met-Leu-Lys (MLK), in which the Leu codon is CUU, near-cognate to the Phe UUU codon. Delivery of Phe-(Cy5) tRNA Phe to immobilized ribosomes initiated with fMet-(Cy3) tRNA fMet in the P site tested the ability of the ribosome to distinguish between cognate and near-cognate tRNA in the A site. Without drugs and in the presence of apramycin, few detectable tRNA FRET events were observed. Thus, the ribosome was able to discriminate against the near-cognate tRNA; mRNA-independent binding events did not produce FRET and so were not detected in these experiments (Blanchard et al., 2004a) . In the presence of paromomycin, we observed many detectable tRNA FRET events on the near-cognate CUU codon (A) FRET between Cy3-labeled P-site tRNA and incoming Cy5-labeled A-site tRNA can be used to track tRNA selection. The evolution of this FRET signal reports on the dynamic decoding and accommodation of the A-site tRNA as well as classical to hybrid fluctuations of the tRNA upon peptide bond formation (Blanchard et al., 2004b) . (B) An example trace from a tRNA-tRNA FRET experiment without aminoglycosides on an MFK mRNA. The traces from tRNA-tRNA FRET experiments are then postsynchronized to have the first appearance of FRET to be t = 0. The condition for each panel is listed in the title. Figure S4 for additional tRNA-tRNA FRET experiments and Table S1 for lifetimes of tRNA events.
( Figures S4D and S4E ). Similar to the cognate mRNA experiment, we observed short excursions to high FRET as well as longer-lived (1$5 s) high-FRET events that showed very limited classical/hybrid fluctuations. The overall lifetime of tRNA FRET in these experiments (1.4$1.9 s) was unchanged as compared to tRNA FRET lifetimes on the cognate MFK mRNA with paromomycin. In contrast to the MFK cognate experiment, about 10% of longer-lived events (1$3 s) were locked in a medium-FRET state ($0.5), consistent with progression to EF-Tu GTPase activation but not full A-site accommodation (Lee et al., 2007) . Pape and coworkers previously observed reduced rates of EF-Tu conformational change and tRNA accommodation after GTPase activation on a near-cognate codon by the addition of paromomycin (Pape et al., 2000) . Overall, however, the behavior of tRNA on the cognate MFK and near-cognate MLK mRNAs was remarkably similar in the presence of paromomycin. These results further support the view that paromomycin interferes with the ribosome in distinguishing between cognate and near-cognate tRNA.
The Apramycin Binding Site on the Ribosome Is Distinct from that of Other Aminoglycosides To explore the structural origins of apramycin function, we determined the NMR solution structure of apramycin in complex with a 27-nucleotide RNA duplex that mimics the A site of the ribosome and the primary binding site of the aminoglycoside antibiotics . The NMR structure of paromomycin and gentamicin C with this model A-site oligonucleotide were previously published Yoshizawa et al., 1998) , and crystal structures with both oligonucleotide and ribosomal particles are available Franç ois et al., 2005) . Data on the RNA-apramycin complex were acquired on both unlabeled and uniformly 13 C, 15 N-labeled RNAs (Lukavsky et al., 2003; Lukavsky and Puglisi, 2005) . A total of 623 nuclear Overhauser effect (NOE) distance restraints, including 32 drug-RNA NOEs, 111 dihedral restraints, and 23 residual dipolar coupling restraints were used in the structure calculations. The conformation of the drug-RNA interface was well defined by the NMR data: the root-mean-square deviation of the core RNA (U1406-U1410; A1490-U1495) and apramycin for the final 32 lowest energy structures was 1.21 Å (PDB ID 2M4Q).
As with all previous aminoglycoside-RNA complexes, including paromomycin and gentamicin C1a, apramycin binding to the A site was guided by interaction of the 2-deoxystreptamine ring with G1494 and U1495 ( Figures 5 and S5 ) through hydrogen bonding interactions with N7 position of G1494 and the O4 position of U1495. However, the rigid structure of apramycin led to a distinct binding mode compared to that in the NMR structures of paromomycin-and gentamicin-RNA Yoshizawa et al., 1998) . Apramycin did not penetrate deeply in to the aminoglycoside binding pocket formed by A1408, A1492, and A1493, instead making stabilizing interactions with the phosphate backbone. As a result, apramycin did not stabilize the extrahelical, or destacked, conformation of A1492 and A1493 observed in the presence of paromomycin and other miscoding aminoglycosides. Apramycin binding to the oligonucleotide in solution favors the intrahelical, or stacked, conformation of the A1408, A1492, and A1493 observed in the structure of the free A-site oligonucleotide . Hygromycin B, another structurally unique, nonarchetypal antibiotic, binds the A site but does not cause destacking of A1492 and A1493; hygromycin B inhibits translocation without causing significant miscoding Cabañ as et al., 1978) .
Effects of Apramycin, Paromomycin, and Gentamicin on Peptide Bond Formation Rates
The intersubunit FRET experiments show that paromomycin and gentamicin inhibit 30S body rotation during elongation. This could result from delays in peptide bond formation due to disruption in tRNA selection or steps subsequent to peptide bond formation. Accordingly, we assayed the effect of the three aminoglycosides on peptide bond formation kinetics in bulk experiments, as previously described (Johansson et al., 2011) . The rates of GTP hydrolysis (k GTP ) and dipeptide formation (k pep ) for all three drugs remained unchanged compared to no drugs ( Figure 6 ). As a control, we also measured the rate of formation of tripeptide (fMet-Phe-Phe) in each case ( Figure S6 ). The rate of disappearance of f[ 3 H]Met, reflecting the rate of dipeptide formation, was also the same in each case. The rate of formation of tripeptides was, however, significantly decreased by the presence of each one of the drugs, in line with all three drugs slowing down the ribosome in elongation. These results suggest that the fraction of drug-bound ribosomes was close to 100% in the experiments.
DISCUSSION
Aminoglycosides are thought to affect translation by decreasing the fidelity of tRNA selection and blocking translocation. We employed a battery of complementary single-molecule methods, supported by structural and biochemical techniques, to form a coherent picture of the mechanism of action for three structurally distinct antibiotics: paromomycin, gentamicin C, and apramycin ( Figure 7 ). The overall structures of the paromomycin and gentamicin RNA structures are also shown in light gray for comparison, but apramycin is not shown for clarity. See also Figure S5 and Table S2 .
Apramycin Slows Translation via One Primary Inhibition Mechanism
Apramycin has the clearest but the most atypical mode of action. The NMR solution structure of the apramycin-ribosomal RNA complex suggested a distinct structural mechanism for inhibition of translocation. The apramycin structure shows that the drug binds in the major groove of the 16S rRNA decoding site similar to other aminoglycosides. However, the drug does not induce the destacked conformation of A1492/A1493, as observed during correct codon-anticodon pairing. This differs with X-ray crystal structures showing A1492/A1493 destacked for all aminoglycosides (see Extended Discussion). However, the recent crystal structure of apramycin bound to the 30S subunit-tRNAmRNA complex suggests that the drug would block unstacking of A1492 (Matt et al., 2012) , consistent with this interpretation. The bias for a stacked conformation of A1492/A1493 in the presence of apramycin is supported by lower level of miscoding observed here and by others (Matt et al., 2012) . This bias could additionally reduce the impact of apramycin on elongation dynamics over cognate codons prior to 30S body rotation, as evidenced by the normal nonrotated lifetime in intersubunit FRET, behavior in tRNA-tRNA FRET that is indistinguishable from no drugs, low tRNA sampling frequency in the ZMW (see Extended Discussion), and lack of effect on cognate k pep .
Apramycin mainly blocks translocation; it significantly lengthens the rotated state lifetime, where the 70S complex is waiting for EF-G in order to translocate. While a previous single-molecule work (Feldman et al., 2010) has correlated inhibition in translocation to perturbations in tRNA conformational dynamics, apramycin breaks this trend, as it strongly inhibits translocation without inducing any noticeable increase in the represent SD as calculated from the fitting procedure averaged over two separate experiments (Johansson et al., 2011) . See also Figure S6 .
occupancy of the classical tRNA conformational state in our tRNA-tRNA FRET experiment. Apramycin may instead lock the A site in an unfavorable conformation for EF-G, effectively increasing the energy barrier that EF-G must overcome to translocate. Similar effects have been observed for the translocation inhibitor spectinomycin, which binds the 30S subunit . Apramycin inhibits the rate of elongation for about ten codons into the message, yet it gradually wears off such that the rotated-state lifetime has mostly recovered by the end of our 6(FK) mRNA. This suggests that the early phase of translation is more vulnerable to antibiotic action.
Paromomycin and Gentamicin Exhibit More Complex Modes of Action
Paromomycin disrupts multiple aspects of elongation, consistent with the conformational changes observed by structural methods. By favoring the destacked A1492/A1493 conformation , it causes severe miscoding in our stop codon readthrough assay. From tRNA-tRNA FRET experiments with a near-cognate codon (MLK) mRNA, the many observable events suggest that paromomycin slows the dissociation of an incorrect tRNA from the A site, consistent with prior kinetic measurements (Pape et al., 2000) . Strikingly, paromomycin still retained half of its miscoding effect in our miscoding assay, where only the noncognate tRNA Phe (to the stop codon) was present. As the total tRNA concentration in the experiment is halved, this result suggests tentatively that destacking of A1492/A1493 can induce miscoding with any tRNA available. The incorrect pulse sequence in ZMW experiments with paromomycin further demonstrates that the ribosome has lost its ability to distinguish correct codon-anticodon interactions. The effects of paromomycin on elongation appear during both global conformational states of the ribosome and sometimes in a codon-specific manner. The frequent short tRNA FRET events indicate that the ribosome goes through many futile cycles where it accepts a tRNA into the A site, bypassing initial selection, but eventually rejects it. The high tRNA FRET level suggests that the A-site tRNA has proceeded beyond GTP hydrolysis by EF-Tu. Normal bulk peptide bond formation rate suggests that some tRNAs proceed as far as transferring the peptide chain from the P-site tRNA to the A-site tRNA. Combined with the increased nonrotated state lifetime in intersubunit FRET experiments, this suggests that paromomycin significantly increases the energy barrier to 30S body rotation, decoupling it from peptide bond formation. If a ribosome stalls early in elongation with a short peptide chain, it could risk losing the A-site tRNA by dissociation. Such ribosomes are left with a deacylated P-site tRNA and are unable to translocate normally, even when a correct tRNA binds in the A site, as indicated by the frequent short-lived binding events observed in the ZMW for stalled traces. Eventually, the ribosome might translocate spontaneously with an acylated A-site tRNA bound and reset itself with an amino acid on the P-site tRNA; however, accumulation of prematurely released peptidyl-tRNA could be toxic. Consistent with that hypothesis, some traces that halted at the first codon in both intersubunit FRET and ZMW experiments subsequently resumed accommodating tRNAs ( Figure 3F ). These severely malfunctioning ribosomes can also become candidates for termination by release factors in vivo (Dunkle and Cate, 2010) , aborting translation after significant energy expenditure.
Paromomycin additionally prolongs the rotated state in general; however, this effect is weaker than apramycin. Paromomycin limits the classical/hybrid tRNA FRET fluctuations, favoring the classical state, which is not conducive for translocation, consistent with observations of Feldman et al. (2010) . Alternatively, the stabilized, destacked conformation of A1492 and A1493 may conflict with EF-G function to reset the ribosome (Taylor et al., 2007) . For both mechanisms, paromomycin effectively increases the energy barrier for the ribosome to translocate. Additionally, paromomycin can significantly lengthen the rotated lifetime of the first codon, but this is only observed at 10 mM paromomycin concentration. This suggests the presence of a secondary binding site; however, the mechanism for this codon-specific effect is not clear.
Gentamicin C, which also promotes the destacked A1492/ A1493 conformation upon binding, induces miscoding as paromomycin. Gentamicin causes a similar increase in rotated ribosome lifetimes as well as locks the tRNAs into the classical conformation in tRNA-tRNA FRET experiments (Feldman et al., 2010) . Additionally, gentamicin induces short-lived tRNAbinding events, like paromomycin in ZMW experiments. Unlike paromomycin, gentamicin increases the energy barrier to ribosome rotation across all codons, resulting in more severe disruptions than paromomycin. Gentamicin is 4,6 linked, and its ring III element contacts G1405 in the decoding site , whereas the additional ring contacts in 4,5 disubstituted aminoglycosides occur to the helical stem closed by C1409-G1491 . These different contacts and their effects on local and global ribosomal dynamics may explain the different mechanistic observations. Alternatively, secondary binding sites may also contribute. Intriguingly, gentamicin has the strongest inhibitory effect and is the most important of the three drugs in clinical applications.
Dissecting the Complex Effects of Aminoglycosides from Multiple Perspectives
By employing complementary single-molecule techniques, buttressed by structure and biochemical assays, our results provide a comprehensive understanding of aminoglycoside mechanisms. Their mode of action is far from simple and involves significant modifications to the delicate energy landscape of elongation. Aminoglycosides have distinct profiles of elongation inhibition, and their structural diversity indeed translates into a diversity of mechanisms. While aminoglycosides are thought to be effective by inducing miscoding and hindering 
. Aminoglycosides Disrupt Various Steps of Elongation
(A) In a normal elongation cycle, ribosome rotation occurs quickly after peptide bond formation between the A-and P-site tRNAs, allowing the tRNAs to fluctuate between the classical and hybrid states. EF-G then translocates and counterrotates the ribosome, moving the tRNAs into the P and E sites to reset the ribosome for another round of elongation. (B) Apramycin does not hinder the rotation of the ribosome upon peptide bond formation; however, it blocks the translocation step where EF-G is involved. This mode of action differs from other members of the aminoglycoside family. (C) Paromomycin and gentamicin display a more complex set of effects on elongation, slowing down both the rotation of the ribosome and translocation as well as inducing severe miscoding. With the ribosome stalled, the A-site tRNA could eventually dissociate with the short peptide chain due to a finite off-rate for tRNAs on the ribosome, leading to a stalled ribosome. translocation, we have observed significant differences in the level of miscoding and effects on steps not directly linked to translocation, which for paromomycin and gentamicin were stronger than their effects on translocation. Despite the complexity of their mechanism, a common theme emerges where they significantly increase energy barriers for the ribosome subunits to rotate and to translocate. As the 1.5-to 4-fold inhibitions over each codon to various steps of the elongation cycle accumulate across multiple codons, these drugs can effectively stall the ribosome and cause severe disruptions to elongation. In fact, even with our 12-codon model mRNA, we already see a dramatic decrease in the number of codons translated during our observation timeframe. These observations agree with the original discussions of Kurland (Kurland, 1987) and others that aminoglycosides are bacteriocidal because of their inhibition of elongation efficiency, not miscoding. How the local conformational changes caused by aminoglycoside binding to the 30S decoding site affect the global behavior of the ribosome and how miscoding aminoglycosides modify the balance of tRNA selection fidelity versus efficiency remain open questions (Johansson et al., 2012) .
EXPERIMENTAL PROCEDURES Single-Molecule Reagents and Buffers
Fluorescently labeled 30S (Cy3 or Cy3B) and 50S (Cy5) ) were prepared as previously described (Blanchard et al., 2004b; Dorywalska et al., 2005; Marshall et al., 2008) . All experiments were conducted in a Tris-based polymix buffer consisting of 50 mM Tris-acetate (pH 7.5), 100 mM potassium chloride, 5 mM ammonium acetate, 0.5 mM calcium acetate, 5 mM magnesium acetate, 0.5 mM EDTA, 5 mM putrescine-HCl, and 1 mM spermidine. All experiments also contained 4 mM GTP. The aminoglycosides used in this study were purchased from Sigma as dry powders and dissolved in water to make stock solutions.
The 5 0 biotinylated mRNAs for the intersubunit FRET and ZMW experiments contained the 5 0 UTR and Shine-Dalgarno sequence of T4 gene 32 followed by either three Phe (UUU) codons (3F) or six alternating Phe (UUC) and Lys (AAA) codons (6(FK)). Both 6(FK) and 3F have a stop codon after the end of the message followed by an additional 4 Phe (UUU) codons . The mRNAs for tRNA-tRNA FRET experiments either contain the full T4 gene 32 sequence up to the 7 th translated codon (MFK) or have the second translated codon changed from Phe (UUU) to a Leu (CUU) (MLK). All mRNAs were chemically synthesized by Dharmacon.
NMR Solution Structure of Apramycin in Complex with A-Site Oligonucleotide Mimic
Near-complete assignment of the proton resonances from the apramycin-RNA complex was accomplished using standard multidimensional, homonuclear, and heteronuclear experiments with unlabeled RNA, and uniformly 13 C, 15 N-labeled RNA samples (Lukavsky et al., 2003; Lukavsky and Puglisi, 2005) . A total of 612 nuclear Overhauser effect (NOE) distance restrains were determined from two-dimensional (2D) and three-dimensional (3D) NOE spectroscopy (NOESY) experiments, of which 32 were intermolecular RNA-apramycin distance restraints. Distance restraints were categorized based on peak intensity into four groups with the following interproton distances: strong (1.8-3.5 Å ), medium (2.0-4.5 Å ), weak (2.2-6.0 Å ), and very weak (3.0-7.0 Å ). Dihedral restrains, b, ε, c, were determined from 3D HCP, 3D heteronuclear multiple quantum coherence (HMQC) total correlation spectroscopy (TOCSY), and 2D NOESY experiments, respectively. Residual dipolar coupling restraints from aromatic N-H and C-H bond vectors were determined by comparing J-coupling constants collected from 2D 13C/15N transverse relaxation optimized spectroscopy (TROSY) spectra in the presence and absence of pf1 bacteriophage. Residual dipolar couplings (RDCs) were determined according to the following formula:
where 1 D XH is the dipolar coupling and 1 J XH is the one bond scalar coupling for X = 13 C or 15 N. The magnitude of C-H RDCs were normalized to those collected for N-H bonds. A breakdown of the restraints used to determine the structure of the apramycin-RNA complex is shown in Table S2 . Structures were calculated according to a previously published multistep simulated annealing protocol using only distance and dihedral restraints during the first stage implemented in XPLOR (Wimberly et al., 1993) . RDCs were incorporated into the structure determination during a second stage, as described previously in CNS (Lynch et al., 2003) .
Intersubunit FRET Experiments
We mixed 0.25 mM Cy3B-30S, preincubated with stoichiometric S1, 1 mM IF2, 1 mM fMet-tRNA fMet , 1 mM 5 0 biotinylated mRNA, and 4 mM GTP to form 30S preinitiation complexes (PICs) in the Tris-based polymix buffer described above to form 30S PICs (Dorywalska et al., 2005) . The PIC mixture was incubated at 37 C for 5 min.
Before immobilizing the 30S PICs on a slide surface, we diluted the mixture with the Tris-based polymix buffer with 1 mM IF2 and 4 mM GTP. The PICs were then immobilized on the surface of a biotin-polyethylene glycol (PEG)-derivatized quartz slide via biotin-neutravidin interactions. We then washed excessive unbound material with the Tris-based polymix buffer containing 1 mM IF2, 4 mM GTP, 1 mM Trolox (to stabilize Cy5 photophysics), and an oxygenscavenging system (2.5 mM 3,4-dihydroxybenzoic acid and 250 nM protocatechuate deoxygenase; Aitken et al., 2008) . We delivered 50 nM Cy5-50S, 1 mM IF2, 80 or 160 nM EF-G, 80 nM ternary complexes, and aminoglycosides (where applicable at the indicated concentration) in the Tris-based polymix buffer using a controlled syringe pump to initiate translation. Phe-tRNA Phe and Lys-tRNA Lys ternary complexes with EF-Tu(GTP) were formed immediately before delivery, as previously described .
ZMW Experiments
The preparation for ZMW experiments was the same as intersubunit experiments with the following exceptions. The first incubation mixture contains 0.25 mM unlabeled wild-type 30S, 0.25 mM wild-type 50S, 1 mM fMet-(Cy3) tRNAfMet, 1 mM 5 0 biotinylated mRNA, and 4 mM GTP to form 70S initiation complexes (ICs). The 70S ICs are then immobilized using the same procedure as in intersubunit FRET experiments. The delivery mixture contained 1 mM IF2, 200 nM EF-G, 200 nM Phe-(Cy5)tRNA Phe ternary complexes, 200 nM Lys-(Cy2)tRNA Lys ternary complexes, and 10 mM paromomycin, apramycin, or gentamicin, comparable to intersubunit FRET conditions.
tRNA-tRNA FRET Experiments
The preparation for tRNA-tRNA FRET experiments was the same as ZMW experiments with the following exception. The delivery mixture contains 1 mM IF2, 500 nM EF-G (where applicable), 25 nM Phe-(Cy5)tRNA Phe ternary complexes, and 10 mM aminoglycosides (where applicable).
Bulk Kinetic Experiments
Bulk kinetic experiments were performed at 20 C and pH 7.5 in polymix buffer (95 mM KCl, 5 mM NH 4 Cl, 5 mM Mg(OAc) 2 , 0.5 mM CaCl 2 , 8 mM putrescine, 1 mM spermidine, 5 mM potassium phosphate, and 1 mM DTE) complemented with an energy supply and regeneration system consisting of 2 mM (ATP + GTP), 10 mM phosphoenolpyruvate, pyruvate kinase, and myokinase (Johansson et al., 2011 by high-performance liquid chromatography (HPLC) as described (Johansson et al., 2011) . The rates of GTP hydrolysis and dipeptide formation were measured in the presence (10 mM) and absence of each drug. The rate of GTP hydrolysis, k GTP , including the association of ternary complex to the ribosome, and the rate of tRNA accommodation/peptidyl transfer, k pep , obtained from the inverse of the difference between the dipeptide formation time and GTP hydrolysis time (Johansson et al., 2011) were estimated in drug absence and in the presence of each one of the drugs. Tripeptide formation was performed by rapid mixing and quenching of mixtures similar to those used for dipeptide bond formation, but with EF-G and EF-Ts added to the ternary complex mix and use of unlabeled rather than labeled GTP. For further details, please refer to Extended Experimental Procedures. While all three drugs effectively inhibit translation elongation, their actions are structurally and mechanistically distinct. Apramycin does not displace A1492 and A1493 at the decoding center, as demonstrated by a solution nuclear magnetic resonance structure, causing only limited miscoding; instead, it primarily blocks translocation. Paromomycin and gentamicin, which displace A1492 and A1493, cause significant miscoding, block intersubunit rotation, and inhibit translocation. Our results show the power of combined dynamics, structural, and biochemical approaches to elucidate the complex mechanisms underlying translation and its inhibition.
SUPPLEMENTAL INFORMATION
INTRODUCTION
We probed the mechanism of translational inhibition by an aminoglycoside from each of the three distinct structural classes: apramycin (fused-ring), paromomycin (4,5-linked), and gentamicin (4,6-linked) ( Figures 1B-1D ) using single-molecule, structural, and biochemical approaches. We solved the solution structure of apramycin bound to the bacterial decoding site by NMR spectroscopy, providing a structure to the repertoire of drug-RNA complexes. We determined the effects of all three drugs on the dynamics of translation using an array of single-molecule techniques : we monitored the global conformation of the ribosome during elongation and the dynamics of tRNA accommodation by fluorescence resonance energy transfer (FRET) (Blanchard et al., 2004a) and used zero-mode waveguides (ZMW) to track multiple tRNAs through several elongation cycles at near physiological concentrations (Levene et al., 2003; Uemura et al., 2010) . We also used bulk kinetics (Johansson et al., 2011) to measure the effects of aminoglycosides on rates of peptide bond formation and subsequent translocation. This combination of single-molecule dynamics, structural, and biochemical techniques reveals the mechanism of aminoglycoside action at an unparalleled level of detail.
RESULTS
Apramycin, Paromomycin, and Gentamicin Target Distinct Aspects of the Elongation Cycle
To monitor the global effects of aminoglycosides on elongation, we used intersubunit FRET between site-specifically labeled Escherichia coli 30S and 50S subunits Dorywalska et al., 2005; Marshall et al., 2008 ) that enable real-time monitoring of single ribosomes performing multiple elongation cycles. For each cycle of elongation, the ribosome rotates the 30S body relative to the 50S and then reverses the rotation, controlled respectively by peptide bond formation upon tRNA accommodation and translocation. The nonrotated state is detected by high FRET and the rotated state by a lower FRET value. The resultant FRET cycles report on the processivity and dynamics of the ribosome at each codon (Figures 2A and  2B ) . All three aminoglycosides significantly inhibited elongation efficiency (Figures S1A-S1C; see Extended Results for details). To probe the mechanistic origins 
. Aminoglycosides Inhibit Translation Elongation at Different Stages
In addition to impacting different phases of elongation, the three aminoglycosides also induce different levels of miscoding, as described in the Extended Results (Figures S1D-S1F ).
In the absence of aminoglycosides, stable binding and transit of multiple tRNAs on the ribosome were observed as regular pulse cycles of repeating Cy5 followed by Cy2 signals with regular times between pulses of 10$20 s ( Figures 3C, 3D , and S3A-S3C), as observed previously (Uemura et al., 2010) . In the presence of 10 mM apramycin, the time between pulses lengthened significantly to 30$40 s, a nearly 2-fold increase, where the pulse sequence was still recognizable. Addition of 10 mM paromomycin and gentamicin introduces frequent metastable tRNA binding events of the length of 1 $ 5 s, and the sequences of those events do not match the codon sequence of the 6(FK) mRNA used for the experiments ( Figure 3E ). The abundance of these short-lived events complicates the identification of binding events, resulting in accommodation and translocation. See the Extended Results for the detailed analysis on how the aminoglycosides alter tRNA binding behavior (Figures S3D-S3F ). This result is consistent with our intersubunit FRET experiments that both aminoglycosides severely impact tRNA selection.
Following Real-Time tRNA Dynamics in the Presence of Aminoglycosides
To delineate the distinct effects of aminoglycosides on tRNA sampling and selection, we followed FRET between a P-site fMet- (Cy3) Apramycin did not significantly alter the dynamics of tRNA compared to no drugs. In both cases, FRET events proceeded to a high (0.8) FRET state within 100 ms of the appearance of FRET and subsequently fluctuated between high (0.8) and medium (0.5) FRET, consistent with rapid tRNA selection and accommodation and peptide bond formation followed by classical-hybrid dynamics (Blanchard et al., 2004b) . However, apramycin increased the overall tRNA FRET lifetime from 10 s in the absence of drugs to 18 s (Table S1 ). By blocking of translocation, apramycin could prevent the eventual dissociation of tRNA fMet from the E site, preserving FRET.
In contrast, paromomycin significantly altered the behavior of tRNA on the ribosome and induces many short-lived excursions (<1 s) from zero FRET to a high (>0.7) FRET level consistent with accommodated tRNA ( Figure S4F ). These events dropped the total FRET lifetime to 1.7 s. While these events are too long to be tRNA sampling attempts (<30 ms), they are much shorter than normal tRNA accommodation without drugs. Longer-lived (1$5 s) high-FRET events with little to no classical-hybrid state fluctuations were also observed ( Figure S4G ), consistent with single-molecule FRET measurements by Blanchard and coworkers (Feldman et al., 2010) . Together with our ZMW measurements, these data suggest that paromomycin stabilizes tRNAs when they sample the A site and shifts the classicalhybrid tRNA conformation equilibrium strongly toward the classical state. The addition of EF-G enriched longer-lived events, as described in the Extended Results ( Figure S4C) .
Paromomycin Induces Miscoding
To probe how paromomycin alters tRNA selection fidelity, we repeated our tRNA-tRNA FRET experiments with an mRNA encoding Met-Leu-Lys (MLK), in which the Leu codon is CUU, near-cognate to the Phe UUU codon. Delivery of Phe-(Cy5) tRNA Phe to immobilized ribosomes initiated with fMet-(Cy3) tRNA fMet in the P site tested the ability of the ribosome to distinguish between cognate and near-cognate tRNA in the A site. Without drugs and in the presence of apramycin, few detectable tRNA FRET events were observed. Thus, the ribosome was able to discriminate against the near-cognate tRNA; mRNA-independent binding events did not produce FRET and so were not detected in these experiments (Blanchard et al., 2004a) . In the presence of paromomycin, we observed many detectable tRNA FRET events on the near-cognate CUU codon Figure S4 for additional tRNA-tRNA FRET experiments and Table S1 for lifetimes of tRNA events.
As with all previous aminoglycoside-RNA complexes, including paromomycin and gentamicin C1a, apramycin binding to the A site was guided by interaction of the 2-deoxystreptamine ring with G1494 and U1495 (Figures 5 and S5 ) through hydrogen bonding interactions with N7 position of G1494 and the O4 position of U1495. However, the rigid structure of apramycin led to a distinct binding mode compared to that in the NMR structures of paromomycin-and gentamicin-RNA Yoshizawa et al., 1998) . Apramycin did not penetrate deeply in to the aminoglycoside binding pocket formed by A1408, A1492, and A1493, instead making stabilizing interactions with the phosphate backbone. As a result, apramycin did not stabilize the extrahelical, or destacked, conformation of A1492 and A1493 observed in the presence of paromomycin and other miscoding aminoglycosides. Apramycin binding to the oligonucleotide in solution favors the intrahelical, or stacked, conformation of the A1408, A1492, and A1493 observed in the structure of the free A-site oligonucleotide . Hygromycin B, another structurally unique, nonarchetypal antibiotic, binds the A site but does not cause destacking of A1492 and A1493; hygromycin B inhibits translocation without causing significant miscoding Cabañ as et al., 1978) .
Effects of Apramycin, Paromomycin, and Gentamicin on Peptide Bond Formation Rates
The intersubunit FRET experiments show that paromomycin and gentamicin inhibit 30S body rotation during elongation. This could result from delays in peptide bond formation due to disruption in tRNA selection or steps subsequent to peptide bond formation. Accordingly, we assayed the effect of the three aminoglycosides on peptide bond formation kinetics in bulk experiments, as previously described (Johansson et al., 2011) . The rates of GTP hydrolysis (k GTP ) and dipeptide formation (k pep ) for all three drugs remained unchanged compared to no drugs ( Figure 6) . As a control, we also measured the rate of formation of tripeptide (fMet-Phe-Phe) in each case ( Figure S6 ). The rate of disappearance of f[ 3 H]Met, reflecting the rate of dipeptide formation, was also the same in each case. The rate of formation of tripeptides was, however, significantly decreased by the presence of each one of the drugs, in line with all three drugs slowing down the ribosome in elongation. These results suggest that the fraction of drug-bound ribosomes was close to 100% in the experiments.
DISCUSSION
Aminoglycosides are thought to affect translation by decreasing the fidelity of tRNA selection and blocking translocation. We employed a battery of complementary single-molecule methods, supported by structural and biochemical techniques, to form a coherent picture of the mechanism of action for three structurally distinct antibiotics: paromomycin, gentamicin C, and apramycin (Figure 7) . The overall structures of the paromomycin and gentamicin RNA structures are also shown in light gray for comparison, but apramycin is not shown for clarity. See also Figure S5 and Table S2 .
Apramycin Slows Translation via One Primary Inhibition Mechanism
Apramycin mainly blocks translocation; it significantly lengthens the rotated state lifetime, where the 70S complex is waiting for EF-G in order to translocate. While a previous single-molecule work (Feldman et al., 2010) has correlated inhibition in translocation to perturbations in tRNA conformational dynamics, apramycin breaks this trend, as it strongly inhibits translocation without inducing any noticeable increase in the The extent of hydrolysis of EF-Tu-bound GTP (A) and dipeptide formation (B) were monitored over time upon mixing of Phe-tRNA Phe :EF-Tu:GTP ternary complex with preinitiated 70S ribosomes in the presence or absence of each type of drug, as indicated in the figure. The rate of GTP hydrolysis, k GTP , (C) and the rate of tRNA accommodation/peptidyl transfer, k pep , (D) obtained from the inverse of the difference between the dipeptide formation time and GTP hydrolysis time were estimated for each case. Error bars in (C) and (D) represent SD as calculated from the fitting procedure averaged over two separate experiments (Johansson et al., 2011) . See also Figure S6 .
Paromomycin and Gentamicin Exhibit More Complex Modes of Action
Dissecting the Complex Effects of Aminoglycosides from Multiple Perspectives
By employing complementary single-molecule techniques, buttressed by structure and biochemical assays, our results provide a comprehensive understanding of aminoglycoside mechanisms. Their mode of action is far from simple and involves significant modifications to the delicate energy landscape of elongation. Aminoglycosides have distinct profiles of elongation inhibition, and their structural diversity indeed translates into a diversity of mechanisms. While aminoglycosides are thought to be effective by inducing miscoding and hindering (A) In a normal elongation cycle, ribosome rotation occurs quickly after peptide bond formation between the A-and P-site tRNAs, allowing the tRNAs to fluctuate between the classical and hybrid states. EF-G then translocates and counterrotates the ribosome, moving the tRNAs into the P and E sites to reset the ribosome for another round of elongation. (B) Apramycin does not hinder the rotation of the ribosome upon peptide bond formation; however, it blocks the translocation step where EF-G is involved. This mode of action differs from other members of the aminoglycoside family. (C) Paromomycin and gentamicin display a more complex set of effects on elongation, slowing down both the rotation of the ribosome and translocation as well as inducing severe miscoding. With the ribosome stalled, the A-site tRNA could eventually dissociate with the short peptide chain due to a finite off-rate for tRNAs on the ribosome, leading to a stalled ribosome. translocation, we have observed significant differences in the level of miscoding and effects on steps not directly linked to translocation, which for paromomycin and gentamicin were stronger than their effects on translocation. Despite the complexity of their mechanism, a common theme emerges where they significantly increase energy barriers for the ribosome subunits to rotate and to translocate. As the 1.5-to 4-fold inhibitions over each codon to various steps of the elongation cycle accumulate across multiple codons, these drugs can effectively stall the ribosome and cause severe disruptions to elongation. In fact, even with our 12-codon model mRNA, we already see a dramatic decrease in the number of codons translated during our observation timeframe. These observations agree with the original discussions of Kurland (Kurland, 1987) and others that aminoglycosides are bacteriocidal because of their inhibition of elongation efficiency, not miscoding. How the local conformational changes caused by aminoglycoside binding to the 30S decoding site affect the global behavior of the ribosome and how miscoding aminoglycosides modify the balance of tRNA selection fidelity versus efficiency remain open questions (Johansson et al., 2012) .
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Bulk Kinetic Experiments
Bulk kinetic experiments were performed at 20 C and pH 7.5 in polymix buffer (95 mM KCl, 5 mM NH 4 Cl, 5 mM Mg(OAc) 2 , 0.5 mM CaCl 2 , 8 mM putrescine, 1 mM spermidine, 5 mM potassium phosphate, and 1 mM DTE) complemented with an energy supply and regeneration system consisting of 2 mM (ATP + GTP), 10 mM phosphoenolpyruvate, pyruvate kinase, and myokinase (Johansson et al., 2011 by high-performance liquid chromatography (HPLC) as described (Johansson et al., 2011) . The rates of GTP hydrolysis and dipeptide formation were measured in the presence (10 mM) and absence of each drug. The rate of GTP hydrolysis, k GTP , including the association of ternary complex to the ribosome, and the rate of tRNA accommodation/peptidyl transfer, k pep , obtained from the inverse of the difference between the dipeptide formation time and GTP hydrolysis time (Johansson et al., 2011) were estimated in drug absence and in the presence of each one of the drugs. Tripeptide formation was performed by rapid mixing and quenching of mixtures similar to those used for dipeptide bond formation, but with EF-G and EF-Ts added to the ternary complex mix and use of unlabeled rather than labeled GTP. For further details, please refer to Extended Experimental Procedures. Supplemental Information EXTENDED RESULTS
SUPPLEMENTAL INFORMATION
Apramycin, Paromomycin, and Gentamicin Efficiently Inhibit Translation Elongation
Using the intersubunit FRET signal, we assayed the effects of apramycin, paromomycin, and gentamicin on the processivity of individual ribosomes at 80 nM tRNA and 80 nM EF-G. The number of elongation (high-low-high FRET) cycles that each ribosome performed on our 12-codon mRNA is plotted as histograms. Without drugs, many ribosomes translated the entire mRNA with the distribution showing a clear peak at codon 12 ( Figure S1A ). However, in the presence of 1mM aminoglycosides ( Figure S1B ), this peak -representing ribosomes whose translation is limited by mRNA length -disappears, and is replaced by peaks at codons 24 for apramycin, 13 for paromomycin, and 1 for gentamicin, the strongest effect observed. Similar levels of inhibition were observed at 10 mM drug concentration ( Figure S1C ), suggesting that 1 mM is at or above saturating concentration for these effects.
Paromomycin and Gentamicin Induce Misincorporation of tRNAs
To test whether apramycin, paromomycin, and gentamicin promote misincorporation and translocation through near-cognate codons, we followed the intersubunit FRET signal of ribosomes translating an mRNA in which the coding region of three Phe codons (UUU) is followed by a stop codon (UAA), which is near-cognate to Lys (AAA), and then four more Phe codons (UUU). In the presence of Phe-tRNA Phe and Lys-tRNA Lys , ribosomes that do not misincorporate the near-cognate Lys-tRNA Lys should perform three rounds of elongation; the fraction of ribosomes that performs more than three rounds of elongation reports on the degree of miscoding in this stop codon readthrough assay within our observation timeframe ( Figures S1D-S1F ). Due to ribosome slippage on poly-U mRNAs and differences in the compositions of translation systems between different studies, the miscoding frequencies reported are relative and not interpreted as absolute miscoding rates. In the absence of aminoglycosides, this miscoding frequency is 2.5%, establishing the baseline of translational fidelity for our assay. In 10 mM apramycin the miscoding frequency triples to 7.5%. Both paromomycin and gentamicin, however, increase this miscoding frequency by an order of magnitude to 30%. Even with only Phe-tRNA Phe (non-cognate to the stop codon), paromomycin still induced 6-fold more misincorporation on 15% of ribosomes. These data suggest that paromomycin and gentamicin severely disrupt, whereas apramycin exerts a weaker effect on tRNA selection.
Analysis of ZMW Experiments with Paromomycin and Gentamicin
The lifetimes of tRNA binding events in the presence of aminoglycosides confirm hindered translation elongation during and after tRNA selection. When all visible events were assigned ( Figures S3D-S3F Lys events occupy 0.24 of each trace, approximately 2-fold increases from 0.12 and 0.13 for no aminoglycosides respectively (an occupancy of 1 means that the entire trace is covered by 1 tRNA event). The longer lifetimes and, thus, higher occupancy of tRNA events that apramycin induces are consistent with our intersubunit FRET result that apramycin blocks the EF-G dependent translocation step, which leads to longer tRNA transit times.
The presence of paromomycin affected only the event frequencies, but not the lifetime, consistent with its stronger effect on the tRNA selection step compared to translocation. The overall tRNA lifetimes for both tRNA Phe (3.7 s) and tRNA Lys (4.0 s) were not affected by paromomycin, whereas visible event frequencies increased by 1.5-fold (0.082 s -1 ) for tRNA Phe and 2.9-fold (0.10 s -1 )
for tRNA Lys . Accordingly, the overall occupancy of tRNA events increased significantly by 2.5 times (0.30) for tRNA Phe and 3.2 times (0.41) for tRNA Lys . Paromomycin significantly increased the number of visible tRNA events (>100 ms, the limit of reliably assigning an event), consistent with the structural prediction that paromomycin stabilizes tRNAs in the A site. In the absence of drug, sampling events are < 30 ms and should be rarely observed in 30 frames per second ZMW experiments. Finally, tRNA lifetimes with gentamicin are either longer with tRNA Phe by 3.6-fold (8.0 s) or similar to no drugs with tRNA Lys (3.9 s), which could be the result of many ribosomes stalling over the first Phe codon. The tRNA frequencies in gentamicin either remained similar to no drugs for tRNA Phe (0.058 s -1 ) or increased for tRNA Lys by 2.3-fold (0.080 s -1 ). Overall, the changes in event frequencies were not as significant as for paromomycin. The overall event occupancy for gentamicin is also high at 3.8 times from normal (0.46) for tRNA Phe and 2.4 times (0.31) for tRNA Lys . Gentamicin and paromomycin both act during the tRNA binding and selection stage, with distinct nuances as observed in the other assays.
tRNA-tRNA FRET Dynamics in the Presence of EF-G In experiments without aminoglycosides and with apramycin, adding 500 nM EF-G did not noticeably changed the evolution of the FRET signal upon tRNA binding to the A site. FRET events proceeded to a high (0.8) FRET state within 100 ms of the appearance of FRET and subsequently fluctuated between high (0.8) and medium (0.5) FRET, consistent with rapid tRNA selection and accommodation, and peptide bond formation followed by classical-hybrid dynamics.
With paromomycin, the presence of 500 nM EF-G enriched moderately long-lived (15 s) high FRET (>0.7) events, as shown in the postsynchronized plot, perhaps as a result of EF-G trapping the A-site tRNA. As short tRNA events still dominated, the total FRET lifetime was similarly short at 1.8 s when compared to no EF-G. Figures 2A and 2B for an explanation of the intersubunit FRET experiment. The number of codons decoded by each ribosome can be measured through intersubunit FRET by counting the rounds of high-low-high FRET (rotation and then counter rotation) transitions observed. On the top two rows, the distributions of the number of codons read on the 6(FK) mRNA (A) without drugs (n = 381), (B) with 1 mM of apramycin (n = 429), paromomycin (n = 264), and gentamicin (n = 297), and (C) with 10 mM of apramycin (n = 370), paromomycin (n = 257), and gentamicin (n = 384) are plotted. Without aminoglycosides, many ribosomes translate deep into the 6(FK) mRNA; upon the addition of aminoglycosides, the distributions become skewed toward peaking around codons 14. The extant of inhibition is similar for both 1 and 10 mM drug concentrations. On the bottom two rows, the number of codons read on the 3F mRNA for (D) no aminoglycosides (n = 306) and (E) 10 mM apramycin (n = 243), 10 mM paromomycin (n = 227), and 10 mM gentamicin (n = 255) are plotted. No aminoglycosides and apramycin show few ribosomes cycling past codon 3, while paromomycin and gentamicin greatly increase the fractions past codon 3. Miscoding through the stop codon can be quantified by counting ribosomes reading more than three codons (elongation cycles) as shown in (F). Apramycin induces a noticeable (3-fold) but moderate increase in miscoding. Paromomycin and gentamicin increase miscoding by an order of magnitude. Paromomycin significantly increases the fraction of miscoding ribosomes even without near-cognate tRNA (-Phe). (B) Individual biomolecules immobilized within each well (3000 wells per chip) can be illuminated and visualized through the glass interface, while the incident light cannot propagate far beyond the glass-well interface to excite other molecules in solution. Thus, ZMWs permit single-molecule experiments to be performed at near-physiological concentrations of fluorescent ligands (1 mM) without significant deterioration of the signal to noise ratio. (C) The number of codon read with well-behaved tRNA binding events ZMW experiments can be extracted by counting the number of pulses in the correct color sequence. The results for no aminoglycosides (n = 117) and for 10 mM apramycin (n = 165) are plotted. As paromomycin and gentamicin induces too many short binding events with the wrong sequence, such an analysis was not possible for them. (D-F) Using labeled Phe-(Cy5)tRNA Phe and Lys-(Cy2)tRNA Lys , the lifetimes (D) (fitted to single exponential functions, error bars are SD error) and frequencies (E) of all visible tRNA events (>100 ms) can be characterized in ZMW tRNA transit experiments. Normally, true tRNA sampling events (30 ms) are not visible in these experiments. The average per-molecule occupancy of each tRNA from individual traces (F) gives an indication of the extent each aminoglycoside locks tRNA into the A site. An occupancy of one indicates that the entire trace is occupied by a single tRNA event. For all panels from left to right, the conditions are no aminoglycosides (n = 117), 10 mM apramycin (n = 165), 10 mM paromomycin (n = 155), and 10 mM gentamicin (n = 188). 
